NCT01781702View on ClinicalTrials.gov

Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
PelubiprofenCelebrexRheumatoid Arthritis
Interventions
DRUG

Pelubiprofen 30 mg

DRUG

Celebrex 200 mg

Sponsors
All Listed Sponsors
lead

Daewon Pharmaceutical Co., Ltd.

INDUSTRY

NCT01781702 - Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients | Biotech Hunter | Biotech Hunter